Secukinumab 300 mg + Secukinumab 150 mg
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Psoriatic Arthritis
Conditions
Psoriatic Arthritis
Trial Timeline
Jun 27, 2016 → Dec 5, 2018
NCT ID
NCT02798211About Secukinumab 300 mg + Secukinumab 150 mg
Secukinumab 300 mg + Secukinumab 150 mg is a approved stage product being developed by Novartis for Psoriatic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02798211. Target conditions include Psoriatic Arthritis.
What happened to similar drugs?
9 of 20 similar drugs in Psoriatic Arthritis were approved
Approved (9) Terminated (0) Active (11)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05767034 | Phase 3 | Completed |
| NCT04930094 | Phase 3 | Completed |
| NCT02798211 | Approved | Completed |
Competing Products
20 competing products in Psoriatic Arthritis